{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:02:02Z","timestamp":1773050522429,"version":"3.50.1"},"reference-count":38,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["13\/13\/01"],"award-info":[{"award-number":["13\/13\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Ovarian cancer survival is stage-dependent: Stage I patients have 90% 5-year survival versus 15% for stage IV. Over 70% of patients worldwide are diagnosed at advanced stages. Ovarian cancer presents with non-specific symptoms (abdominal bloating, early satiety, discomfort\/pain, bowel\/urinary changes). Current National Institute for Health and Care Excellence guidelines recommend that symptomatic women presenting to primary care are tested with cancer antigen 125 and ultrasound, then referred to secondary care for further triage if these tests are abnormal.<\/jats:p>\n Current standard of care risk prediction model used to triage women in National Health Service secondary care is Risk of Malignancy Index 1 combining cancer antigen 125 and simple ultrasound features, which at 250 threshold has 70% sensitivity and 90% specificity. Newer models offer potential for improved sensitivity, earlier diagnosis and better survival outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate diagnostic strategies for ovarian cancer in women with non-specific symptoms through systematic review, United Kingdom Collaborative Trial of Ovarian Cancer Screening data set analysis, prospective studies and health economic evaluation comparing Risk of Malignancy Index 1 against newer approaches including Risk of Ovarian Malignancy Algorithm, Ovarian-Adnexal Reporting and Data System and International Ovarian Tumour Analysis models, including International Ovarian Tumour Analysis Assessment of Different NEoplasias in the adneXa.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Four concurrent work packages: (1) Cochrane systematic review; (2) United Kingdom Collaborative Trial of Ovarian Cancer Screening data set model development; (3) prospective multicentre diagnostic accuracy study (ROCkeTS) with parallel pre\/postmenopausal cohorts; and (4) cost\u2013consequence analysis. Allied analyses investigated psychological impact and cancer outcomes from symptom-triggered pathways.<\/jats:p>\n ROCkeTS recruited 2453 women across 23 hospitals (2015\u201323) with symptoms, raised cancer antigen 125 and\/or abnormal imaging. Women completed questionnaires, donated blood and underwent transvaginal ultrasound scored by International Ovarian Tumour Analysis terminology by certified National Health Service sonographers with quality assurance. Reference standard was histology for surgical cases or 12-month wellbeing ascertainment. Primary outcome: primary invasive ovarian cancer versus benign or normal.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The Cochrane systematic review (58 studies, 30,121 patients and 9061 ovarian cancer cases) demonstrated that most published diagnostic test accuracy studies failed to differentiate between pre- and postmenopausal women, and all were conducted in high-prevalence settings, limiting applicability to routine practice.<\/jats:p>\n \n In the ROCkeTS prospective study in premenopausal women, in the initial cohort recruited prior to protocol change (\n n<\/jats:italic>\n \u2005=\u2005857), Risk of Malignancy Index 1 at threshold 250 showed poor sensitivity (42.6%, 95% confidence interval 28.3 to 57.8) but high specificity (96.5%, 95% confidence interval 94.7 to 97.8). All other tests improved sensitivity but dropped specificity. International Ovarian Tumour Analysis Assessment of Different NEoplasias in the adneXa at 10% threshold achieved significantly higher sensitivity (89.1%, 95% confidence interval 76.4 to 96.4), higher than all other tests with acceptable specificity (73.2%, 95% confidence interval 69.9 to 76.4).\n <\/jats:p>\n \n In the ROCkeTS prospective cohort study in postmenopausal women (\n n<\/jats:italic>\n \u2005=\u20051242), Risk of Malignancy Index 1 at 250 demonstrated better performance (82.9%, 95% confidence interval 76.7 to 88.0), but International Ovarian Tumour Analysis Assessment of Different NEoplasias in the adneXa at 10% had the best sensitivity at 96.1% (95% confidence interval 92.2 to 98.4) compared to Risk of Malignancy Index 1 with the least drop of specificity. Risk of Ovarian Malignancy Algorithm at manufacturer recommended threshold and Ovarian-Adnexal Reporting and Data System did not improve on Risk of Malignancy Index 1 sensitivity in postmenopausal women.\n <\/jats:p>\n Cancer prevalence differed between premenopausal (5.7%) and postmenopausal (17%) cohorts. Early-stage cancer (I\/II) were diagnosed in 60.2% of premenopausal and 41% of postmenopausal cohorts. Cancer diagnosis rates were very low (1.6%) in women under 40 years. High anxiety and distress were noted, particularly in younger women. One in four women with high-grade serous ovarian cancers were diagnosed at early stage (I\/II). Complete cytoreduction was achieved in 61.3% of cases, with optimal cytoreduction (\u2264\u20051\u2005cm residual disease) in an additional 15.1%.<\/jats:p>\n Cost\u2013consequence analysis demonstrated that a two-step strategy deployed at the same ultrasound sitting, initially triaging out benign looking tumours on ultrasound, then calculating ovarian cancer risk with International Ovarian Tumour Analysis Assessment of Different NEoplasias in the adneXa ultrasound model at 10% demonstrated the best balance across cost, diagnostic yield and cancer deaths compared to other diagnostic strategies.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Cohort study required key changes to protocol and post-pandemic recruitment was slow.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n International Ovarian Tumour Analysis Assessment of Different NEoplasias in the adneXa ultrasound at 10% threshold, delivered by trained National Health Service sonographers demonstrated superior diagnostic performance compared to Risk of Malignancy Index 1 and should be considered as new standard of care for suspected ovarian cancer in pre- and postmenopausal women. A two-step strategy using International Ovarian Tumour Analysis Assessment of Different NEoplasias in the adneXa offers optimal balance across cost, diagnostic yield and cancer death reduction. Implementation requires sonographer training investment and quality assurance.<\/jats:p>\n <\/jats:sec>\n \n Future research<\/jats:title>\n International Ovarian Tumour Analysis Assessment of Different NEoplasias in the adneXa implementation in primary care\/community settings, artificial intelligence-enabled quality assurance, reconfiguration of referral pathways in primary care to reduce unnecessary referrals in younger women and consequent harm are important research areas. Systematic symptom elicitation capitalising on routine health interactions to reach underserved communities warrants further research.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 13\/13\/01.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/bdhs6485","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T08:16:53Z","timestamp":1757319413000},"page":"1-21","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying the best diagnostic test for ovarian cancer \u2013 synopsis of Refining Ovarian Cancer Test accuracy Scores (ROCkeTS) research"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5843-3015","authenticated-orcid":true,"given":"Sudha","family":"Sundar","sequence":"first","affiliation":[{"name":"Department of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-5617","authenticated-orcid":true,"given":"Ridhi","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Applied Health, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6111-2805","authenticated-orcid":true,"given":"Katie","family":"Scandrett","sequence":"additional","affiliation":[{"name":"Department of Applied Health, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5659-4889","authenticated-orcid":true,"given":"Clare","family":"Davenport","sequence":"additional","affiliation":[{"name":"Department of Applied Health, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1614-2988","authenticated-orcid":true,"given":"Lauren","family":"Sturdy","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-2145","authenticated-orcid":true,"given":"Ryan","family":"Ottridge","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-1971","authenticated-orcid":true,"given":"Jon","family":"Deeks","sequence":"additional","affiliation":[{"name":"Department of Applied Health, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2026,3]]},"reference":[{"key":"key2026030914053500_ref1-bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key2026030914053500_ref2-bib2","volume-title":"Ovarian Cancer Statistics","author":"Cancer Research UK","year":"2015"},{"key":"key2026030914053500_ref3-bib3","volume-title":"NOCA State of the Nation Report 2024","author":"The National Ovarian Cancer Audit (NOCA)"},{"key":"key2026030914053500_ref4-bib4","volume-title":"CRUK Cancer Intelligence ShinyApps","author":"Early Diagnosis Hub"},{"key":"key2026030914053500_ref5-bib5","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet (London, England)"},{"key":"key2026030914053500_ref6-bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ygyno.2023.11.005","article-title":"Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer \u2013 an exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"179","author":"Dilley","year":"2023","journal-title":"Gynecol Oncol"},{"key":"key2026030914053500_ref7-bib7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(23)00335-2","article-title":"Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial","volume":"24","author":"Menon","year":"2023","journal-title":"Lancet Oncol"},{"key":"key2026030914053500_ref8-bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(12)70041-4","article-title":"Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England","volume":"13","author":"Lyratzopoulos","year":"2012","journal-title":"Lancet Oncol"},{"key":"key2026030914053500_ref9-bib9","doi-asserted-by":"crossref","first-page":"g7400","DOI":"10.1136\/bmj.g7400","article-title":"Rethinking diagnostic delay in cancer: how difficult is the diagnosis?","volume":"349","author":"Lyratzopoulos","year":"2014","journal-title":"BMJ"},{"key":"key2026030914053500_ref10-bib10","volume-title":"Suspected Cancer: Recognition and Referral, NICE Guidance [NG12]","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key2026030914053500_ref11-bib11","volume-title":"Pathfinder | Target Ovarian Cancer"},{"key":"key2026030914053500_ref12-bib12","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.3390\/cancers12123730","article-title":"CA125 and ovarian cancer: a comprehensive review","volume":"12","author":"Charkhchi","year":"2020","journal-title":"Cancers"},{"key":"key2026030914053500_ref13-bib13","volume-title":"Ovarian Masses in Premenopausal Women, Management of Suspected (Green-Top Guideline No. 62)","author":"Royal College of Obstetricians and Gynaecologists"},{"key":"key2026030914053500_ref14-bib14","volume-title":"Ovarian Cysts in Postmenopausal Women (Green-Top Guideline No. 34)","author":"Royal College of Obstetricians and Gynaecologists"},{"key":"key2026030914053500_ref15-bib15","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1097\/AOG.0000000000001768","article-title":"Practice Bulletin No. 174: evaluation and management of adnexal masses","volume":"128","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins \u2013 Gynecology","year":"2016","journal-title":"Obstet Gynecol"},{"key":"key2026030914053500_ref16-bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1148\/radiol.2019191150","article-title":"O-RADS US risk stratification and management system: a consensus guideline from the ACR ovarian-adnexal reporting and data system committee","volume":"294","author":"Andreotti","year":"2020","journal-title":"Radiology"},{"key":"key2026030914053500_ref17-bib17","doi-asserted-by":"crossref","first-page":"e010333","DOI":"10.1136\/bmjopen-2015-010333","article-title":"Refining Ovarian Cancer Test accuracy Scores (ROCkeTS): protocol for a prospective longitudinal test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer","volume":"6","author":"Sundar","year":"2016","journal-title":"BMJ Open"},{"key":"key2026030914053500_ref18-bib18","doi-asserted-by":"crossref","first-page":"56.e1","DOI":"10.1016\/j.ajog.2019.07.031","article-title":"Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses","volume":"222","author":"Gentry-Maharaj","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"key2026030914053500_ref19-bib19","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.3390\/cancers14153621","article-title":"Diagnostic models combining clinical information, ultrasound and biochemical markers for ovarian cancer: Cochrane systematic review and meta-analysis","volume":"14","author":"Davenport","year":"2022","journal-title":"Cancers"},{"key":"key2026030914053500_ref20-bib20","article-title":"Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women","volume":"7","author":"Davenport","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026030914053500_ref21-bib21","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.3390\/cancers15133335","article-title":"Evaluating the harms of cancer testing-a systematic review of the adverse psychological correlates of testing for cancer and the effectiveness of interventions to mitigate these","volume":"15","author":"Kwong","year":"2023","journal-title":"Cancers"},{"key":"key2026030914053500_ref22-bib22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/1471-0528.17813","article-title":"Investigating harms of testing for ovarian cancer \u2013 psychological outcomes and cancer conversion rates in women with symptoms of ovarian cancer: a cohort study embedded in the multicentre ROCkeTS prospective diagnostic study","volume":"131","author":"Kwong","year":"2024","journal-title":"BJOG"},{"key":"key2026030914053500_ref23-bib23","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41416-025-03165-4","article-title":"CA125 and age-based models for ovarian cancer detection in primary care: a population-based external validation study","volume":"133","author":"Arendse","year":"2025","journal-title":"Br J Cancer"},{"key":"key2026030914053500_ref24-bib24","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41416-025-03166-3","article-title":"Cost-effectiveness of CA125- and age-informed risk-based triage for ovarian cancer detection in primary care","volume":"133","author":"Wu","year":"2025","journal-title":"Br J Cancer"},{"key":"key2026030914053500_ref25-bib25","doi-asserted-by":"crossref","first-page":"101848","DOI":"10.1136\/ijgc-2024-005371","article-title":"Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer","volume":"36","author":"Kwong","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"key2026030914053500_ref26-bib26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S1470-2045(24)00406-6","article-title":"Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study","volume":"25","author":"Sundar","year":"2024","journal-title":"Lancet Oncol"},{"key":"key2026030914053500_ref27-bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083912","article-title":"Diagnostic tests for ovarian cancer in premenopausal women with non-specific symptoms (ROCkeTS): prospective, multicentre, cohort study","volume":"392","author":"Sundar","year":"2026","journal-title":"BMJ"},{"key":"key2026030914053500_ref28-bib28","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/1471-0528.70074","article-title":"A Cost Consequence Analysis of Seven Diagnostic Strategies for Ovarian Cancer: A Model\u2010Based Economic Evaluation","volume":"133","author":"Perry","year":"2026","journal-title":"BJOG"},{"key":"key2026030914053500_ref29-bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/uog.26080","article-title":"Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort","volume":"61","author":"Landolfo","year":"2023","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026030914053500_ref30-bib30","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S1470-2045(18)30837-4","article-title":"Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study","volume":"20","author":"Froyman","year":"2019","journal-title":"Lancet Oncol"},{"key":"key2026030914053500_ref31-bib31","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S1470-2045(24)00723-X","article-title":"Risk-prediction models and clinical challenges in the ROCkeTS study \u2013 authors\u2019 reply","volume":"26","author":"Sundar","year":"2025","journal-title":"Lancet Oncol"},{"key":"key2026030914053500_ref32-bib32","volume-title":"Top Scoring Abstracts of the RCOG World Congress 2025\u20132025 \u2013 BJOG: An International Journal of Obstetrics & Gynaecology \u2013 Wiley Online Library"},{"key":"key2026030914053500_ref33-bib33","volume-title":"IOTA Plus NHS Training","author":"IOTA Plus","year":"2024"},{"key":"key2026030914053500_ref34-bib34","doi-asserted-by":"crossref","first-page":"102734","DOI":"10.1016\/j.ijgc.2025.102734","article-title":"Transforming ovarian cancer diagnostic pathways (sonata): Roma versus CA125 in community setting for diagnosis of ovarian cancer. A real-world prospective diagnostic test accuracy study \u2013 preliminary results","volume":"35","author":"Sundar","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"key2026030914053500_ref35-bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejogrb.2024.06.025","article-title":"British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024","volume":"300","author":"Moss","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key2026030914053500_ref36-bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41591-024-03329-4","article-title":"International multicenter validation of AI-driven ultrasound detection of ovarian cancer","volume":"31","author":"Christiansen","year":"2025","journal-title":"Nat Med"},{"key":"key2026030914053500_ref37-bib37","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2589-7500(21)00278-8","article-title":"Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic study","volume":"4","author":"Gao","year":"2022","journal-title":"Lancet Digit Health"},{"key":"key2026030914053500_ref38-bib38","volume-title":"Transforming Ovarian Cancer Diagnostic Pathways (TranSforming Ovarian caNcer diAgnosTic pAthways): A Hybrid Type 1 Effectiveness-implementation Study of a Novel Biomarker Based, Threshold Driven Pathway for Earlier Ovarian Cancer Diagnosis","author":"Sundar","year":"2024"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/BDHS6485\/BDHS6485.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:40:22Z","timestamp":1773045622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/BDHS6485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["10.3310\/BDHS6485"],"URL":"https:\/\/doi.org\/10.3310\/bdhs6485","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"10-2014","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"02-2025","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"10-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}